APUS Apimeds Pharmaceuticals: Year-over-year earnings per share growth for the last twelve months

Official company branding of Apimeds Pharmaceuticals, Inc. (APUS)

The success of proprietary apitoxin-based molecules will ensure high margins for Apimeds Pharmaceuticals (APUS) as it scales through partners. Assessing quarterly EPS growth helps identify a reversal in the fundamental trend, where the -455.20 mark serves as a key metric. Currently, the biotech's financial stability is directly tied to the test results of neurological drugs, while operational risks are minimized by delegating research to contract organizations.

Apimeds Pharmaceuticals US (APUS) Earnings per share growth in annualized terms for the last twelve months: for the period 05/10/2025 - 11/14/2026

Analytical breakdowns for Apimeds Pharmaceuticals

- share price and consensus valuation forecast:
Stock Quotes Apimeds Pharmaceuticals US|APUS - Analyst Consensus Forecast
- company stock capitalization data:
Market Value Apimeds Pharmaceuticals US|APUS - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Apimeds Pharmaceuticals|APUS - Total Stockholders' Equity|Market Value to Book Value Ratio apimedsus.com|APUS - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Apimeds Pharmaceuticals|APUS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Apimeds Pharmaceuticals, Inc.|APUS - Company Total Indebtedness|Debt to Book Value Apimeds|APUS - Long-Term Debt|Company Short-Term Debts Apimeds Pharmaceuticals|Quick Liquidity apimedsus.com
- earnings and market multiples details:
APUS - Profit After Tax|Projected Future Earnings Apimeds Pharmaceuticals|APUS - Business Payback Period|Future Price to Earnings Apimeds|APUS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Apimeds|APUS - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Apimeds Pharmaceuticals|APUS - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months apimedsus.com|APUS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Apimeds Pharmaceuticals
- sales volume and revenue indicators:
APUS - Company Sales Revenue|Company Projected Revenue Apimeds Pharmaceuticals US|APUS - Price-to-Sales Ratio|Forward P/S Multiple Apimeds Pharmaceuticals US
Fundamental company analysis:Apimeds Pharmaceuticals, Inc., APUS
Manufactured product of Apimeds Pharmaceuticals

The high scalability of Apimeds Pharmaceuticals (APUS) bee venom-based biotechnologies enables the generation of global revenue with low production costs. This efficiency is reflected in the recorded quarterly EPS growth, which measures the daily rate of change in earnings per share, revealing the impact of external liquidity on real business metrics and warning investors of the risks of overpaying for the asset at its peak profitability.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Larimar Pharma LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada TRDA|Quarterly EPS earnings growth PTHS|Year-over-year net earnings per share growth for the last 12 months MediciNova MNOV|Year-over-year earnings per share growth for the last twelve months Serina Therapeutics SER|Year-over-year net earnings per share change for the last twelve months BioXcel Therapeutics Inc (BTAI)|PMN - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata